Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Current Deferred Revenue (2017 - 2020)

Historic Current Deferred Revenue for Serina Therapeutics (SER) over the last 4 years, with Q4 2020 value amounting to $300000.0.

  • Serina Therapeutics' Current Deferred Revenue rose 600.71% to $300000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $300000.0, marking a year-over-year increase of 600.71%. This contributed to the annual value of $300000.0 for FY2020, which is 600.71% up from last year.
  • Serina Therapeutics' Current Deferred Revenue amounted to $300000.0 in Q4 2020, which was up 600.71% from $255000.0 recorded in Q3 2020.
  • Serina Therapeutics' 5-year Current Deferred Revenue high stood at $407000.0 for Q1 2020, and its period low was $180000.0 during Q4 2017.
  • For the 4-year period, Serina Therapeutics' Current Deferred Revenue averaged around $291600.0, with its median value being $291500.0 (2019).
  • Per our database at Business Quant, Serina Therapeutics' Current Deferred Revenue skyrocketed by 7611.11% in 2018 and then tumbled by 1072.56% in 2019.
  • Over the past 4 years, Serina Therapeutics' Current Deferred Revenue (Quarter) stood at $180000.0 in 2017, then skyrocketed by 76.11% to $317000.0 in 2018, then dropped by 10.73% to $283000.0 in 2019, then increased by 6.01% to $300000.0 in 2020.
  • Its last three reported values are $300000.0 in Q4 2020, $255000.0 for Q3 2020, and $328000.0 during Q2 2020.